A Randomized, Double Blind, Placebo-controlled, Parallel Group, Multicentre, Phase 2a Study to Assess Target Engagement, Safety and Tolerability of AZD4831 in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs AZD 4831 (Primary)
- Indications Heart failure
- Focus Biomarker; Pharmacodynamics
- Acronyms SATELLITE
- Sponsors AstraZeneca
- 30 Sep 2019 Planned End Date changed from 15 Jul 2020 to 13 Oct 2020.
- 30 Sep 2019 Planned primary completion date changed from 15 Jul 2020 to 13 Oct 2020.
- 05 Jun 2019 Planned End Date changed from 22 Apr 2020 to 15 Jul 2020.